Stéphane Bancel: “We are pleased to announce new multiple vaccine candidates, including for enteric viruses, such as norovirus, and targeting Lyme disease, our first bacterial vaccine.”
Photo: Courtesy.
San Salvador. Moderna announced Wednesday clinical and program updates demonstrating the expansion and advancement of its mRNA (messenger RNA) pipeline.
The updates include advances in the company’s portfolio for respiratory viruses and latent viruses, new vaccine candidates, and announcements of commercial and financial frameworks for the respiratory vaccines business.
He added that mRNA-1010, the first investigational seasonal flu vaccine, encourages consistently strong immunogenicity results in the most recent Phase 3 trial against influenza A and titers consistent with non-inferiority against influenza B strains. .
Moderna’s respiratory pipeline includes phase 3 trials against RSV and influenza, and a next-generation COVID-19 candidate. The portfolio includes four additional influenza vaccines with expanded antigens, against other respiratory pathogens, and five combination vaccine schedules.
Moderna continues to meet the changing needs of the COVID-19 endemic market, including through multivalent boosters and by advancing next-generation vaccines.
Although influenza A and B viruses cause seasonal influenza epidemics, influenza A viruses cause the majority of influenza-related hospitalizations in older adults, including more than 95% of hospitalizations in the most recent influenza season .
The company has five flu vaccine candidates in clinical development. mRNA-1010, seasonal quadrivalent vaccine using WHO-recommended strains; mRNA-1011/1012a seasonal penta-/hexavalent vaccine candidate that includes more hemagglutinin antigens to broaden strain compatibility; mRNA-1020/1030a seasonal vaccine candidate that includes neuraminidase antigens to target more conserved regions of the mRNA-1010 virus.
He mRNA-1010 demonstrated an acceptable safety and tolerability profile in the trial, and the independent Data and Safety Monitoring Board (DSMB) for P301 did not identify any safety concerns; he mRNA-1345Moderna’s RSV vaccine candidate, is in a randomized, observer-blind, placebo-controlled trial (ConquerRSV) in adults 60 years and older, randomized.
